GWM
CASC

Gupta Wealth Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Gupta Wealth Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		$1K Hold
83
– – ﹤0.01% 1141
2015
Q4 		$1K Hold
83
– – ﹤0.01% 1227
2015
Q3 		$1K Hold
83
– – ﹤0.01% 1240
2015
Q2 		$2K Hold
83
– – ﹤0.01% 1169
2015
Q1 		$1K Buy
+83
New +$814 ﹤0.01% 1132

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Gupta Wealth Management's CASC Position: Q1 2016 in Review

Gupta Wealth Management held its Cascadian Therapeutics, Inc. (CASC) position steady in Q1 2016 at 83 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1141.

Gupta Wealth Management first reported a position in CASC in Q1 2015 and has held it in 5 quarters since. The position peaked at $2K in Q2 2015. 80 funds tracked by Wall St. Rank hold CASC as of Q1 2016.

  • Gupta Wealth Management held 83 shares of Cascadian Therapeutics, Inc. worth $1K as of Q1 2016.
  • Gupta Wealth Management left its Cascadian Therapeutics, Inc. share count unchanged in Q1 2016.
  • Cascadian Therapeutics, Inc. made up ﹤0.01% of Gupta Wealth Management's portfolio in Q1 2016, its #1141 holding.
  • Gupta Wealth Management first reported a position in Cascadian Therapeutics, Inc. in Q1 2015 and has held it in 5 quarters since.
  • Gupta Wealth Management's Cascadian Therapeutics, Inc. position peaked at $2K in Q2 2015.
  • 80 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2016.

Based on Gupta Wealth Management's 13F filing for Q1 2016, filed 16 May 2016.